Por: RTTNews Health December 05, 2022
Nkarta Inc. () is scheduled to report updated clinical data from its ongoing clinical trial of NKX019, its CD19-directed CAR NK cell therapy candidate, today, December 5.The company is developing allogeneic engineered natural killer (NK) cell therapies to treat cancer.NKX019 is an investigational, off-the-shelf cancer immunotherapy that uses NK cells derived from the peripheral blood of healthy donors and engineered with a chimeric antigen... + full article
RTTNews USA Health October 17, 2023
Biopharmaceutical company Nkarta, Inc. () announced Tuesday the clearance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to evaluate NKX019, its allogeneic, CD19-directed CAR NK cell therapy candidate, for the treatment of lupus... + más
Nkarta | RTTNews
Toni Braxton's Life-Saving Advice for People Living With Lupus | The Root
About iurex | Privacy Policy | Disclaimer |